Governance
Investors

Pipeline

NidlegyTM

Preclinical

Phase I

Phase II

Phase III

Partner

Stage III B,C,D Melanoma (EU) (NCT02938299)

–

–

–

–

Sun Pharma*

Stage III B,C,D Melanoma (US) (NCT03567889)

–

–

–

–

Sun Pharma* 

+ Pembrolizumab – Stage IV Melanoma (US) (NCT06284590)

–

–

–

–

Sun Pharma* 

Non-Melanoma skin cancer basket trial (EU) (NCT04362722)

–

–

–

–

Sun Pharma* 

Non-Melanoma skin cancer basket trial (EU) (NCT05329792)

–

–

–

–

Sun Pharma* 

1st line locally advanced basal cell carcinoma (efficacy characterization study) (EU + US)  (NCT07227350)

–

–

–

–

Sun Pharma*

3rd line locally advanced basal cell carcinoma (EU + US) (NCT07227870)

–

–

–

–

Sun Pharma* 

3rd line locally advanced basal cell carcinoma (EU + US) (NCT07227870)

–

–

–

–

Sun Pharma* 

2nd line locally advanced cutaneous squamous cell carcinoma (EU + US) (NCT07228442)

–

–

–

–

Sun Pharma* 

* Partnered in Europe, Australia and New Zealand

Fibromun

Preclinical

Phase I

Phase II

Phase III

Partner

+ Doxorubicin – 1st line Soft-Tissue Sarcoma (EU) (NCT04650984)

–

–

–

–

Sun Pharma

+ Doxorubicin – 1st line Leiomyosarcoma (US) (NCT03420014)

–

–

–

–

Sun Pharma

+ Dacarbazine – pre-treated Soft-Tissue Sarcoma (EU)(NCT04733183)

–

–

–

–

Sun Pharma

+ Lomustine – recurrent Glioma (EU) (NCT04573192)

–

–

–

–

Sun Pharma

+ Lomustine – recurrent Glioma (US) (NCT06336291)

–

–

–

–

Sun Pharma

+ Radiation + Temozolomide – 1st line Glioma (EU) (NCT04443010)

–

–

–

–

Sun Pharma

Darleukin

Preclinical

Phase I

Phase II

Phase III

+ Radiation – Non-Small Cell Lung Cancer (NCT03705403)

–

–

–

–

Dodekin

Preclinical

Phase I

Phase II

Phase III

Various Solid Tumors (NCT04471987)

–

–

–

–

Dekavil

Preclinical

Phase I

Phase II

Phase III

Partner

Chronic Inflammation (NCT07245992)

–

–

–

–

Pfizer

OncoFAP Radio Conjugates (Imaging)

Preclinical

Phase I

Phase II

Phase III

Partner

Various Solid Tumors (NCT05784597)

–

–

–

–

Bracco

OncoFAP Radio Conjugates (Therapy)

Preclinical

Phase I

Phase II

Phase III

Various Solid Tumors (NCT06640413)

–

–

–

–

OncoFAP-GlyPro-MMAE

Preclinical

Phase I (animal patients)

Phase II

Phase III

Various Solid Tumors

–

–

–

–

OncoACP3 (Imaging)

Preclinical

Phase I

Phase II

Phase III

Partner

Prostate Cancer (NCT06840535)

–

–

–

–

RayzeBio

OncoACP3 (Therapy)

Preclinical

Phase I

Phase II

Phase III

Partner

Prostate Cancer

–

–

–

–

RayzeBio

OncoCAIX

Preclinical

Phase I

Phase II

Phase III

Renal Cell Carcinoma (NCT06840548)

–

–

–

–